[ Price : $8.95]
FDA issues Bristol-Myers Squibb a complete response letter on its NDA for daclatasvir, an NS5A complex inhibitor for use in combin...[ Price : $8.95]
FDA accepts Revive Therapeutics IND for bucillamine as a potential new gout treatment.[ Price : $8.95]
Indias Dr. Reddys says it will immediately implement remediations called for in a recent FDA inspection at its active pharmaceutic...[ Price : $8.95]
FDA approves Grifols new plasma facility in Clayton, NC and will begin production next year.[ Price : $8.95]
CDRH deputy director for science William Maisel criticizes a Brigham and Womens Hospital clinical study for using now-restricted l...[ Price : $8.95]
FDAs Minneapolis District Office warns Nemschoff Chairs about Medical Device Reporting violations involving its Serenity patient c...[ Price : $8.95]
FDA extends by three months its review of a Novartis NDA for LBH589 (panobinostat) for use in combination with bortezomib and dexa...[ Price : $8.95]
In its latest batch of Warning Letters, FDA cites Avena Botancials, Bodyhealth.com, Ebola-C Inc., Excelsior Medical, Navilyst Medi...